Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5551/jat.58362 http://scihub22266oqcxt.onion/10.5551/jat.58362 33116032!8147570!33116032     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33116032&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Atheroscler+Thromb 2021 ; 28 (4): 396-401 Nephropedia Template TP {{tp|p=33116032|t=2021. Management of a COVID-19 Patient during ECMO: Paying Attention to Acquired von Willebrand Syndrome |pdf=|usr=}}{{33116032}} gab.com Text Management of a COVID-19 Patient during ECMO: Paying Attention to Acquired von Willebrand Syndrome JO: J Atheroscler Thromb http://www.kidney.de/pget.php?&tw=1&pmid=33116032 #FOAvip Patients with severe COVID-19 often experience complications including coagulopathy and fatal thrombosis. COVID-19 pneumonia sometimes leads to acute respiratory distress syndrome, requiring extracorporeal membrane oxygenation (ECMO), during which thrombosis and bleeding are major causes of death. Anticoagulation such as heparin is essential for COVID-19 patients on ECMO; however, bleeding might be caused by not only heparin, but also acquired von Willebrand syndrome (AVWS). To date, no study has examined ECMO-related bleeding and AVWS in COVID-19 patients.We report a COVID-19 patient who experienced bleeding from AVWS in addition to disseminated intravascular coagulation (DIC) during ECMO. The level of high-molecular weight VWF multimers decreased during ECMO therapy, and these findings promptly improved after discontinuation of ECMO. Plasma levels of VWF antigen were extremely high, probably due to endothelial cell damage caused by COVID-19. On the other hand, plasma levels of ADAMTS13 activity were moderately reduced, to 20-30% of normal. The patient was successfully treated with cryoprecipitate in bleeding during ECMO without a reduction in heparin, which might have induced thromboembolism. Bleeding found in this patient might be caused by AVWS and DIC.Severe COVID-19 patients are in a thrombotic state and need to receive anticoagulant therapy. However, once they receive ECMO therapy, bleeding symptoms could be observed. In such cases, physicians should think of AVWS in addition to the side effect of heparin and DIC. Twit Text FOAVip Management of a COVID-19 Patient during ECMO: Paying Attention to Acquired von Willebrand Syndrome ????J Atheroscler Thromb http://www.kidney.de/pget.php?&tw=1&pmid=33116032 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33116032 #FOAvip English Wikipedia <ref>{{Cite pmid|33116032}}</ref> Management of a COVID-19 Patient during ECMO: Paying Attention to Acquired von Willebrand Syndrome #MMPMID33116032 Hayakawa M; Takano K; Kayashima M; Kasahara K; Fukushima H; Matsumoto M J Atheroscler Thromb 2021[Apr]; 28 (4): 396-401 PMID33116032show ga Patients with severe COVID-19 often experience complications including coagulopathy and fatal thrombosis. COVID-19 pneumonia sometimes leads to acute respiratory distress syndrome, requiring extracorporeal membrane oxygenation (ECMO), during which thrombosis and bleeding are major causes of death. Anticoagulation such as heparin is essential for COVID-19 patients on ECMO; however, bleeding might be caused by not only heparin, but also acquired von Willebrand syndrome (AVWS). To date, no study has examined ECMO-related bleeding and AVWS in COVID-19 patients.We report a COVID-19 patient who experienced bleeding from AVWS in addition to disseminated intravascular coagulation (DIC) during ECMO. The level of high-molecular weight VWF multimers decreased during ECMO therapy, and these findings promptly improved after discontinuation of ECMO. Plasma levels of VWF antigen were extremely high, probably due to endothelial cell damage caused by COVID-19. On the other hand, plasma levels of ADAMTS13 activity were moderately reduced, to 20-30% of normal. The patient was successfully treated with cryoprecipitate in bleeding during ECMO without a reduction in heparin, which might have induced thromboembolism. Bleeding found in this patient might be caused by AVWS and DIC.Severe COVID-19 patients are in a thrombotic state and need to receive anticoagulant therapy. However, once they receive ECMO therapy, bleeding symptoms could be observed. In such cases, physicians should think of AVWS in addition to the side effect of heparin and DIC. |Anticoagulants/therapeutic use[MESH] |COVID-19/*complications/*therapy[MESH] |Disseminated Intravascular Coagulation/complications/therapy[MESH] |Extracorporeal Membrane Oxygenation/adverse effects/*methods[MESH] |Hemorrhage[MESH] |Heparin/pharmacology[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Thromboembolism/complications[MESH] |von Willebrand Diseases/*complications/therapy[MESH]Management of a COVID-19 Patient during ECMO: Paying Attention to Acqu(epmc).pdf DeepDyve Pubget Overpricing